KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

CRISPR Therapeutics AG's Long-Term Investments history spans 5 years, with the latest figure at $28.4 million for Q3 2025.

  • For Q3 2025, Long-Term Investments changed N/A year-over-year to $28.4 million; the TTM value through Sep 2025 reached $28.4 million, changed N/A, while the annual FY2023 figure was $2.0 million, 96.29% down from the prior year.
  • Long-Term Investments for Q3 2025 was $28.4 million at CRISPR Therapeutics AG, up from $11.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $77.1 million in Q3 2022 and bottomed at $2.0 million in Q4 2023.
  • The 4-year median for Long-Term Investments is $9.8 million (2022), against an average of $23.9 million.
  • The largest annual shift saw Long-Term Investments tumbled 96.29% in 2023 before it soared 128.57% in 2024.
  • A 4-year view of Long-Term Investments shows it stood at $53.1 million in 2022, then crashed by 96.29% to $2.0 million in 2023, then soared by 467.66% to $11.2 million in 2024, then soared by 153.68% to $28.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Long-Term Investments are $28.4 million (Q3 2025), $11.2 million (Q2 2024), and $2.0 million (Q4 2023).